Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Michael Woike"'
Autor:
Annemarie Uhlig, Johannes Uhlig, Michael Woike, Thomas Fischer, Lutz Trojan, Lothar Bergmann, Martin Bögemann, Peter J. Goebell, Michael Rink, Katrin Schlack, Marianne Leitsmann, Arne Strauß
Publikováno v:
Kidney Cancer. :1-12
Objective: To evaluate the effectiveness and safety profile of the tyrosine kinase inhibitor Axitinib for patients with advanced or metastatic renal cell carcinoma (a/mRCC) in a real-world setting. Methods: Adult patients from the German non-interven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb01df865a420f1aad736639a9bfc20b
https://doi.org/10.3233/kca-220011
https://doi.org/10.3233/kca-220011
Autor:
Peter Jürgen Goebell, Johanna Buncke, Katrin Schlack, Martin Boegemann, Andres J. Schrader, Michael Woike
Publikováno v:
Transl Androl Urol
BACKGROUND: Temsirolimus is a mTOR inhibitor approved for the first-line treatment of advanced or metastatic renal cell carcinoma (a/mRCC) with poor prognosis. In treatment of a/mRCC several prognostic scoring systems are used. We assessed the progno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e36c57ac75f7a1970f81751cd6d5c3e
https://doi.org/10.21037/tau-20-938
https://doi.org/10.21037/tau-20-938
Publikováno v:
Future oncology (London, England). 17(1)
The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5b8464857d5b9ce995cf7f71c16c4c6
https://pubmed.ncbi.nlm.nih.gov/33275038
https://pubmed.ncbi.nlm.nih.gov/33275038
Autor:
M. Schmid, Lothar Bergmann, M. Boegemann, Arne Strauss, T. Fischer, Michael Rink, Michael Woike, K. Schlack, G. Krekeler
Publikováno v:
Annals of Oncology. 30:v386
Background Antacids (AA) are commonly used in the elderly population. Proton pump inhibitors and other drugs to neutralize the gastral pH level and to prevent gastroesophageal reflux are suspected to reduce the efficacy of tyrosine kinase inhibitors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bfe0c707373c3720f7c0c156dda1823
https://doi.org/10.1093/annonc/mdz249.051
https://doi.org/10.1093/annonc/mdz249.051
Publikováno v:
Journal of Clinical Oncology. 35:441-441
441 Background: In treatment of metastatic renal cell carcinoma (mRCC) patients several prognostic scores are used: the MSKCC-, IMDC-, and for pts treated with Temsirolimus (TEMS) the Hudes-score. We assessed prognostic value of these scores in TEMS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc249b85cb36c1eb3216a71bc25b4862
https://doi.org/10.1200/jco.2017.35.6_suppl.441
https://doi.org/10.1200/jco.2017.35.6_suppl.441
Autor:
Michael Woike, Wolfgang Jeitschko
Publikováno v:
Journal of Solid State Chemistry. 129:312-319
The nine title compounds were prepared by reaction of multiple-phase rare earth silicide oxide powders with nitrogen. Single crystals of the erbium compound were isolated from a sample, which had been melted in a high-frequency furnace. Two slightly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::097300565da44a2fefc88c10c99e40b2
https://doi.org/10.1006/jssc.1996.7258
https://doi.org/10.1006/jssc.1996.7258
Autor:
Wolfgang Jeitschko, Michael Woike
Publikováno v:
Inorganic Chemistry. 34:5105-5108
The chemical preparation of rare earth nitridosilicates of the formula types, Ln{sub 3}Si{sub 6}N{sub 11} and LnSi{sub 3}N{sub 5} is reported. The samarium example (Sm{sub 3}Si{sub 6}N{sub 11}) was characterized by X-ray crystallography. The LnSi{sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22ebd9478353b39d151af3edf5d9c345
https://doi.org/10.1021/ic00125a005
https://doi.org/10.1021/ic00125a005
Autor:
P. J. Goebell, H. Harich, E. Herrmann, T. Steiner, Michael Woike, T. Göhler, D. Kalanovic, Lothar Bergmann, U. Rebmann
Publikováno v:
Annals of Oncology. 25:iv296
serious adverse events were observed in 72.2 % and 42.3 % of the pts (drug related in 41.3 % and 9.5% of the pts), respectively (n = 496). Most common drug-related toxicities (incidence ≥3%) of any grade were fatigue (7.3 %), rash (5.4 %), pruritus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8d809c237ba201ae93dcb88a4b1c7d5
https://doi.org/10.1093/annonc/mdu337.43
https://doi.org/10.1093/annonc/mdu337.43
Publikováno v:
Journal of Clinical Oncology. 30:4631-4631
4631 Background: Several novel targeted agents significantly prolong overall survival (OS) in metastatic renal cell cancer (mRCC) patients (pts.). Translational research, however, has not identified any prospectively validated prognostic or predictiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b85070c1e5179e6e6865ad63dea49f7
https://doi.org/10.1200/jco.2012.30.15_suppl.4631
https://doi.org/10.1200/jco.2012.30.15_suppl.4631
Publikováno v:
Oncology Research & Treatment. 2020 Supplement, Vol. 43, p1-292. 293p.